Decrease in active hepatitis C infection among people who use drugs in Madrid, Spain, 2017 to 2023: a retrospective study
Background: People who use drugs (PWUD) are a key target population to reduce the burden of hepatitis C virus (HCV) infection. Aim: To assess risk factors and temporal trends of active HCV infection in PWUD in Madrid, Spain. Methods: We conducted a retrospective study between 2017 and 2023, includin...
| Autores: | , , , , , , , |
|---|---|
| Tipo de documento: | artigo |
| Data de publicação: | 2024 |
| País: | España |
| Recursos: | Instituto de Salud Carlos III (ISCIII) |
| Repositório: | Repisalud |
| Idioma: | inglês |
| OAI Identifier: | oai:repisalud.isciii.es:20.500.12105/26428 |
| Acesso em linha: | https://hdl.handle.net/20.500.12105/26428 |
| Access Level: | Acceso aberto |
| Palavra-chave: | Hepatitis C Spain Epidemiology Mobile screening unit People who inject drugs People who use drugs Adult Drug Users Female Hepacivirus Hepatitis C Antibodies Humans Male Middle Aged Prevalence Retrospective Studies Risk Factors Risk-Taking Sexual Behavior Substance Abuse, Intravenous Substance-Related Disorders Surveys and Questionnaires Young Adult |
| Resumo: | Background: People who use drugs (PWUD) are a key target population to reduce the burden of hepatitis C virus (HCV) infection. Aim: To assess risk factors and temporal trends of active HCV infection in PWUD in Madrid, Spain. Methods: We conducted a retrospective study between 2017 and 2023, including 2,264 PWUD visiting a mobile screening unit. Data about epidemiology, substance use and sexual risk behaviour were obtained through a 92-item questionnaire. HCV was detected by antibody test, followed by RNA test. The primary outcome variable was active HCV infection prevalence, calculated considering all individuals who underwent RNA testing and analysed by logistic regression adjusted by the main risk factors. Results: Of all participants, 685 tested positive for anti-HCV antibodies, and 605 underwent RNA testing; 314 had active HCV infection, and 218 initiated treatment. People who inject drugs (PWID) were identified as the main risk group. The active HCV infection rate showed a significant downward trend between 2017 and 2023 in the entire study population (23.4% to 6.0%), among PWID (41.0% to 15.0%) and PWUD without injecting drug use (7.0% to 1.3%) (p < 0.001 for all). These downward trends were confirmed by adjusted logistic regression for the entire study population (adjusted odds ratio (aOR): 0.78), PWID (aOR: 0.78), and PWUD non-IDU (aOR: 0.78). Conclusions: Our study demonstrates a significant reduction in active HCV infection prevalence among PWUD, particularly in PWID, which suggests that efforts in the prevention and treatment of HCV in Madrid, Spain, have had an impact on the control of HCV infection. |
|---|